Abstract:
The present invention more particularly relates to a process for the preparation of cephalosporin antibiotics of the formula (I) wherein R 1 represents hydrogen, trityl, CH 3 , CR a R b COORY c where R a and R b independently represent hydrogen or methyl and R c represents hydrogen or (C 1 -C 6 )alkyl; R 2 is carboxylate ion or COOR d , where R d represents hydrogen, ester or a counter ion which forms a salt; R 3 represents hydrogen, CH 3 , CH 2 OCOCH 3 , CH=CH 2 .
Abstract translation:本发明更具体地涉及一种制备式(I)的头孢菌素抗生素的方法,其中R 1表示氢,三苯甲基,CH 3,CR a R b COOR cc,其中R a和R b独立地表示氢或甲基,R c表示氢或(C 1 -C 6) 烷基; R2是羧酸根离子或COORd,其中Rd表示氢,酯或形成盐的抗衡离子; R3表示氢,CH3,CH2OCOCH3,CH = CH2。
Abstract:
The present invention relates to a novel, cost-effective process for the preparation of Sterile Meropenem Trihydrate, which is prepared by a) condensation of l-Azabicyclo[3.2.0]hepta-2-ene-2-carboxylic acid, 3- [(diphenoxyphosphinyl)oxy]-6-(l-hydroxyethyl)-4-methyl-7-oxo-(4-nitrobenzyl) methyl ester,[4R-[4a,5b,6b(R*)]] with (2S,4S)-2-(Dimethylaminqcarbonyl)-4- mercapto-l -(p-nitrobenzyloxycarbonyl)-l -pyrrolidine to obtain diprotected Meropenem; b) deprotection and hydrogenation of diprotected Meropenem to obtain non-sterile Meropenem Trihydrate; c) conversion of NS Meropenem Trihydrate into Sterile Meropenem Trihydrate by using water, methanolic ammonia solution and purging carbon dioxide gas.
Abstract:
The present invention discloses a novel, cost-effective process for preparation of [R-[R*,R*-(E)]]-2,2'-(l,8-dioxo-4-octene-l,8-diyl) bis(oxy- 3, 1-propanediyl) bis(l,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-l-[(3,4,5- trimethoxyphenyl)- methyl] isoquinolinium) dichloride, commonly known as mivacurium chloride, which avoids the conversion of (E)-4-octene-l,8-dioic acid to its acid chloride and use of non-ionic polymeric adsorbent resin to get a highly pure product.
Abstract:
The present invention provides an improved process for the preparation of cefixime of formula (I) from the corresponding alkyl ester, with an improved quality having/possessing better color and solubility. The ester hydrolysis is carried out in a biphasic system by using sodium bicarbonate and sodium hydroxide.
Abstract:
The present invention relates to an improved process for the preparation of cefadroxil of the Formula (I), more particularly, the present invention relates to an improved process for the preparation of cefadroxil having water content in the range of 4-5 %.
Abstract:
The present invention provides an improved process for the preparation of 7-amino-3-[2-(furylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid represented by formula (I) (I)by the condensation of 7-amino cephalosporanic acid (7-ACA) represented by formula (II) with furyl-2-carbonylthiol represented by formula (III) using borontrifluoride as condensing agent in an organic solvent at a temperature range of 20 °-50 °C.
Abstract:
The present invention relates to a novel, cost-effective process for the preparation of Sterile Meropenem Trihydrate, which is prepared by a) condensation of l-Azabicyclo[3.2.0]hepta-2-ene-2-carboxylic acid, 3- [(diphenoxyphosphinyl)oxy]-6-(l-hydroxyethyl)-4-methyl-7-oxo-(4-nitrobenzyl) methyl ester,[4R-[4a,5b,6b(R*)]] with (2S,4S)-2-(Dimethylaminqcarbonyl)-4- mercapto-l -(p-nitrobenzyloxycarbonyl)-l -pyrrolidine to obtain diprotected Meropenem; b) deprotection and hydrogenation of diprotected Meropenem to obtain non-sterile Meropenem Trihydrate; c) conversion of NS Meropenem Trihydrate into Sterile Meropenem Trihydrate by using water, methanolic ammonia solution and purging carbon dioxide gas.